Early vs late anticoagulation in acute ischemic stroke with indications outside atrial fibrillation

• Published in: Journal of stroke and cerebrovascular diseases Vol. 33; no. 7; p. 107757
• Main Authors: Jumah, Ammar, Fu, Siyuan, Albanna, Abdalla Jamal, Agarwal, Utkarsh, Fana, Michael, Choudhury, Omar, Idris, Anas, Elfaham, Abdelrahman, Iqbal, Zahid, Schultz, Lonni, Latack, Katie, Brady, Megan, Scozzari, Dawn, Ramadan, Ahmad Riad
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2024
• Subjects: Acute ischemic stroke; Anticoagulation; Intracranial hemorrhage; Thromboembolism; Thrombosis; Intracranial hemorrhage; Anticoagulation; Thromboembolism; Acute ischemic stroke; Thrombosis
• ISSN: 1052-3057; 1532-8511
• DOI: 10.1016/j.jstrokecerebrovasdis.2024.107757

Current literature lacks guidance on the safety of administering anticoagulation in acute ischemic stroke with emergent indications that require anticoagulation other than atrial fibrillation. Therefore, we tend to rely on studies investigating acute ischemic stroke in atrial fibrillation for anticoagulation recommendations. We retrospectively reviewed data for patients with acute ischemic stroke who had a non-atrial fibrillation emergent indication for anticoagulation (e.g., intra-arterial thrombus, intracardiac thrombus, acute coronary syndrome, acute limb ischemia, deep vein thrombosis and pulmonary embolism) diagnosed within 3 days of acute ischemic stroke. Patients who received anticoagulation ≤ 3 days of stroke onset (Group A) were compared to those who either received it afterwards or did not receive it at all (Group B). Out of the 558 patients, only 88 patients met our inclusion criteria. Of the total cohort, 55.7 % patients were males, and basic demographics were similar in both groups except for milder strokes in Group A (national institute of health stroke scale 6 vs. 12.5, p = 0.03). Only 2 patients in Group A and 1 patient in Group B developed intracranial hemorrhage, which was not statistically significant. Group A patients had a lower incidence of both new diagnosis (2 % vs. 34.2 % %, p < 0.001) and propagation of an established venous thromboembolism. They also had a lower rate of any thromboembolic complication (2 % vs. 42 %, p < 0.001). Early anticoagulation (i.e., ≤ 3 days) in non-atrial fibrillation ischemic stroke patients with an emergent indication may be safe and carry a lower risk of thromboembolic complications than later anticoagulation.